Blood test may reveal which lymphoma patients will respond to immunotherapy
The RNA signature offers a clue about the tumor microenvironment: the mix of immune, structural and blood vessel cells around a tumor. It does not require doctors to collect a tumor sample. Instead, researchers look for a pattern in cell-free RNA found in plasma, the liquid part of blood. In this study, the pattern resembled a “lymph node-like” environment previously linked to better CAR T-cell outcomes in biopsy samples. Patients whose plasma showed that signature tended to have higher scores if they responded to treatment. The signal was not found in matched samples of immune cells circulating in the blood. That absence suggests the plasma RNA may reflect activity in tissue rather than changes in the blood’s cellular makeup. The signature was associated with outcomes, but the study has not shown that using it changes care or improves survival. Larger studies are needed to test whether it works reliably in other patient groups and settings.
What does the blood test’s RNA signature reveal about a lymphoma tumor?
The RNA signature offers a clue about the tumor microenvironment: the mix of immune, structural and blood vessel cells around a tumor. It does not require doctors to collect a tumor sample. Instead, researchers look for a pattern in cell-free RNA found in plasma, the liquid part of blood.
In this study, the pattern resembled a “lymph node-like” environment previously linked to better CAR T-cell outcomes in biopsy samples. Patients whose plasma showed that signature tended to have higher scores if they responded to treatment. The signal was not found in matched samples of immune cells circulating in the blood.
That absence suggests the plasma RNA may reflect activity in tissue rather than changes in the blood’s cellular makeup. The signature was associated with outcomes, but the study has not shown that using it changes care or improves survival. Larger studies are needed to test whether it works reliably in other patient groups and settings.
Among the 91 patients studied, how did the risk of cancer progression differ between those with high and low signature scores?
Among the 91 lymphoma patients studied, those with high scores on the plasma RNA signature had an 80% lower risk of cancer progression than those with low scores. The score was measured before treatment, so the result suggests a possible way to identify patients with different outlooks before CAR T-cell therapy.
The signature reflected a “lymph node-like” tumor environment. Patients who responded to treatment had higher plasma RNA scores than nonresponders, matching an earlier finding from tumor tissue. Across three patient groups, people with above-median scores also had significantly longer survival.
This is a difference in observed risk, not proof that the test itself prevents progression. The researchers checked whether the score simply tracked tumor burden and found no significant correlation with the standard proxy lactate dehydrogenase before chemotherapy preparation. The authors say larger, multi-institution studies must validate the findings; the test has not been shown to improve patient outcomes.
What is anti-CD19 CAR T-cell therapy, and how does it help the immune system attack lymphoma?
Anti-CD19 CAR T-cell therapy is a treatment in which a patient’s own immune cells are engineered to hunt cancer. The article describes it as a major advance for large B-cell lymphoma, an aggressive blood cancer, but notes that not every patient responds or stays in remission.
The therapy uses a patient’s immune cells after they have been engineered. In standard medical terminology, CD19 is a target found on B cells, the cell type involved in this lymphoma; the article itself describes the cells as engineered to hunt cancer. The study examined patients receiving a particular CAR T-cell therapy product at Dana-Farber Cancer Institute.
Outcomes remain difficult to predict: nearly half of patients either fail to respond or relapse within a year. The new blood-based RNA signature could potentially help identify patients more likely to benefit, but it does not change or explain how the therapy works. The researchers say the model needs validation in larger, multi-institution groups.
Why might the cells and other features surrounding a tumor affect whether CAR T-cell therapy works?
A tumor’s microenvironment includes the immune, structural and blood vessel cells around the cancer. Recent research cited in the article has pointed to this neighborhood as an important factor in CAR T-cell response. The idea matters because a patient’s cancer cells are not the only features that may be associated with treatment success.
A 2025 study sorted lymphomas into three environment types using biopsy samples. Tumors with a “lymph node-like” environment fared better with CAR T therapy. Two other patterns—one dominated by exhausted T cells and another by follicular macrophages and accessory cells—were linked to treatment failure. The blood study found a matching lymph node-like signature in patients who responded.
These findings show associations, not a fully established explanation of how each cell type affects the therapy. The plasma signature was absent from circulating immune cells, suggesting it reflects tissue activity. More research is needed to validate the pattern and determine how doctors might use it; the study did not show that changing the environment improves outcomes.
If a patient has a low signature score, what might doctors consider doing—and has this test yet been shown to improve outcomes?
A low score may indicate that a patient’s tumor environment lacks the signature associated with better CAR T-cell outcomes. The researchers envision using the test to identify patients with unfavorable environments before the cells are infused. That could give doctors information about risk before treatment, but the article does not specify what care change should follow a low result.
In the study, patients with high scores had a lower risk of progression than those with low scores. The signature was measured in plasma before treatment and resembled a tissue pattern previously associated with response. It was also associated with outcomes beyond the clinical factors included in the researchers’ statistical models.
The findings are not yet a basis for claiming that a low score should prompt a particular alternative or intervention. The authors call for validation in larger, multi-institution patient groups and across different contexts. They explicitly note that the findings have not been shown to change patient outcomes, so the test remains under study rather than a proven way to improve care.
Why could a blood sample offer a useful alternative to taking a tumor biopsy?
A blood sample could be useful because collecting plasma is minimally invasive, while obtaining tissue for a biopsy can be invasive. The researchers wanted to know whether blood could provide clues about the tumor microenvironment, which earlier work had examined using biopsy samples.
They analyzed cell-free RNA in plasma collected before treatment. The blood-based signature resembled the “lymph node-like” pattern seen in tumor tissue, and patients who responded had higher scores than nonresponders. The signal was absent from matched samples of immune cells circulating in the blood, suggesting the plasma RNA reflected activity in tissue rather than a change in blood-cell makeup.
The results point to a possible way to assess the tumor neighborhood with a blood draw, but they do not establish a ready-to-use clinical test. The model needs validation in larger, multi-institution groups and other patient contexts. The study also has not shown that using the test changes treatment decisions or improves outcomes.
What is RNA, and how can patterns of gene activity give clues about what cells are doing?
RNA is a molecule involved in using genetic instructions. The source article describes cell-free RNA as fragments of genetic material shed by cells into the bloodstream. It does not explain RNA’s wider role in detail; in basic biology, cells use different kinds of RNA to help carry out gene instructions and make proteins.
A gene expression signature is a pattern in which genes are active, inferred from the RNA associated with them. In this study, researchers looked for such a pattern in plasma RNA before treatment. The resulting signature resembled a “lymph node-like” tumor environment and was linked to differences in patient outcomes.
RNA patterns can therefore offer clues about what cells may be doing, but this study’s result is an association, not a full account of the underlying biology. The signature was absent from matched circulating immune cells, suggesting that plasma RNA may reflect tissue activity. The authors say the model needs validation in larger and more varied groups before its clinical usefulness is clear.
This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.
Read more in the JupiteX app
Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.
Or read more news on the web